APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Malaria

Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a parasite, Plasmodium, which belongs to a group of one-celled organisms known as protozoa. The only way to get malaria is to be bitten by a certain type of mosquito that has bitten someone who has the disease.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a parasite, Plasmodium, which belongs to a group of one-celled organisms known as protozoa. The only way to get malaria is to be bitten by a certain type of mosquito that has bitten someone who has the disease.

Anti-malarial Drugs are available only with a physician's prescription. They come in tablet, capsule, and injectable forms. Among the commonly used anti-malarial drugs are chloroquine, mefloquine, primaquine, pyrimethamine, and quinine.

Selected research

Market Analysis & Forecast

Global Drugs for Malaria Market Analysis and Forecast 2026-2032

2 January 2026191 pages

Choose your research edition.

Industry ResearchDrugs for Malaria Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Malaria Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Drugs for Malaria Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Malaria Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Malaria Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

Drugs for malaria or antimalarial medications are also known as anti-malarial drugs. Anti-malarial drugs treat or Prevention malaria, a disease that occurs in tropical, subtropical, and some temperate regions of the world. The disease is caused by a parasite, Plasmodium, which belongs to a group of one-celled organisms known as protozoa. The only way to get malaria is to be bitten by a certain type of mosquito that has bitten someone who has the disease.

Anti-malarial Drugs are available only with a physician's prescription. They come in tablet, capsule, and injectable forms. Among the commonly used anti-malarial drugs are chloroquine, mefloquine, primaquine, pyrimethamine, and quinine.

In the U.S. market, the major manufacturers are Cipla, Guilin Southern Medicine, IPCA Laboratories, GlaxoSmithKline, Mylan Labs, Roche, Novartis, Sanofi Aentis and Ajanta Pharma, etc, with about 73% market shares.

Read the full market overview

Report Includes

This report presents an overview of global market for Drugs for Malaria, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drugs for Malaria, also provides the revenue of main regions and countries. Of the upcoming market potential for Drugs for Malaria, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs for Malaria revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drugs for Malaria market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drugs for Malaria revenue, projected growth trends, production technology, application and end-user industry.

Drugs for Malaria Segment by Company

Cipla

Guilin Pharmaceutical

IPCA Laboratories

GlaxoSmithKline

Mylan Labs

Roche

Novartis

Sanofi Aventis

Ajanta Pharma

Drugs for Malaria Segment by Type

Aryl Aminoalcohol Compounds

Antifolate Compounds

Artemisinin Compounds

Drugs for Malaria Segment by Application

Prevention

Treatment

Others

Drugs for Malaria Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Malaria market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Malaria and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Malaria.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drugs for Malaria in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drugs for Malaria company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for Malaria revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drugs for Malaria Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Aryl Aminoalcohol Compounds Major Player Table 3. Antifolate Compounds Major Player Table 4. Artemisinin Compounds Major Player Table 5. Global Drugs for Malaria Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Prevention Major Player Table 7. Treatment Major Player Table 8. Others Major Player Table 9. Drugs for Malaria Industry Trends Table 10. Drugs for Malaria Industry Drivers Table 11. Drugs for Malaria Industry Opportunities and Challenges Table 12. Drugs for Malaria Industry Restraints Table 13. Global Drugs for Malaria Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Drugs for Malaria Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Drugs for Malaria Market Share by Region (2021-2026) Table 16. Global Drugs for Malaria Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Drugs for Malaria Market Share by Region (2027-2032) Table 18. Global Drugs for Malaria Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Drugs for Malaria Revenue Market Share by Players (2021-2026) Table 20. Global Drugs for Malaria Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Drugs for Malaria Key Players Headquarters & Area Served Table 22. Global Drugs for Malaria Players, Product Type & Application Table 23. Global Drugs for Malaria Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Drugs for Malaria by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Drugs for Malaria Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Drugs for Malaria Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Drugs for Malaria Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Drugs for Malaria Revenue Market Share by Type (2021-2026) Table 30. Global Drugs for Malaria Revenue Market Share by Type (2027-2032) Table 31. Global Drugs for Malaria Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Drugs for Malaria Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Drugs for Malaria Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Drugs for Malaria Revenue Market Share by Application (2021-2026) Table 35. Global Drugs for Malaria Revenue Market Share by Application (2027-2032) Table 36. Cipla Company Information Table 37. Cipla Business Overview Table 38. Cipla Drugs for Malaria Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Cipla Drugs for Malaria Product Portfolio Table 40. Cipla Recent Development Table 41. Guilin Pharmaceutical Company Information Table 42. Guilin Pharmaceutical Business Overview Table 43. Guilin Pharmaceutical Drugs for Malaria Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Guilin Pharmaceutical Drugs for Malaria Product Portfolio Table 45. Guilin Pharmaceutical Recent Development Table 46. IPCA Laboratories Company Information Table 47. IPCA Laboratories Business Overview Table 48. IPCA Laboratories Drugs for Malaria Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. IPCA Laboratories Drugs for Malaria Product Portfolio Table 50. IPCA Laboratories Recent Development Table 51. GlaxoSmithKline Company Information Table 52. GlaxoSmithKline Business Overview Table 53. GlaxoSmithKline Drugs for Malaria Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. GlaxoSmithKline Drugs for Malaria Product Portfolio Table 55. GlaxoSmithKline Recent Development Table 56. Mylan Labs Company Information Table 57. Mylan Labs Business Overview Table 58. Mylan Labs Drugs for Malaria Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Mylan Labs Drugs for Malaria Product Portfolio Table 60. Mylan Labs Recent Development Table 61. Roche Company Information Table 62. Roche Business Overview Table 63. Roche Drugs for Malaria Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Roche Drugs for Malaria Product Portfolio Table 65. Roche Recent Development Table 66. Novartis Company Information Table 67. Novartis Business Overview Table 68. Novartis Drugs for Malaria Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Novartis Drugs for Malaria Product Portfolio Table 70. Novartis Recent Development Table 71. Sanofi Aventis Company Information Table 72. Sanofi Aventis Business Overview Table 73. Sanofi Aventis Drugs for Malaria Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Sanofi Aventis Drugs for Malaria Product Portfolio Table 75. Sanofi Aventis Recent Development Table 76. Ajanta Pharma Company Information Table 77. Ajanta Pharma Business Overview Table 78. Ajanta Pharma Drugs for Malaria Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Ajanta Pharma Drugs for Malaria Product Portfolio Table 80. Ajanta Pharma Recent Development Table 81. North America Drugs for Malaria Revenue by Type (2021-2026) & (US$ Million) Table 82. North America Drugs for Malaria Revenue by Type (2027-2032) & (US$ Million) Table 83. North America Drugs for Malaria Revenue by Application (2021-2026) & (US$ Million) Table 84. North America Drugs for Malaria Revenue by Application (2027-2032) & (US$ Million) Table 85. North America Drugs for Malaria Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 86. North America Drugs for Malaria Revenue by Country (2021-2026) & (US$ Million) Table 87. North America Drugs for Malaria Revenue by Country (US$ Million) & (2027-2032) Table 88. Europe Drugs for Malaria Revenue by Type (2021-2026) & (US$ Million) Table 89. Europe Drugs for Malaria Revenue by Type (2027-2032) & (US$ Million) Table 90. Europe Drugs for Malaria Revenue by Application (2021-2026) & (US$ Million) Table 91. Europe Drugs for Malaria Revenue by Application (2027-2032) & (US$ Million) Table 92. Europe Drugs for Malaria Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. Europe Drugs for Malaria Revenue by Country (2021-2026) & (US$ Million) Table 94. Europe Drugs for Malaria Revenue by Country (US$ Million) & (2027-2032) Table 95. China Drugs for Malaria Revenue by Type (2021-2026) & (US$ Million) Table 96. China Drugs for Malaria Revenue by Type (2027-2032) & (US$ Million) Table 97. China Drugs for Malaria Revenue by Application (2021-2026) & (US$ Million) Table 98. China Drugs for Malaria Revenue by Application (2027-2032) & (US$ Million) Table 99. Asia Drugs for Malaria Revenue by Type (2021-2026) & (US$ Million) Table 100. Asia Drugs for Malaria Revenue by Type (2027-2032) & (US$ Million) Table 101. Asia Drugs for Malaria Revenue by Application (2021-2026) & (US$ Million) Table 102. Asia Drugs for Malaria Revenue by Application (2027-2032) & (US$ Million) Table 103. Asia Drugs for Malaria Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 104. Asia Drugs for Malaria Revenue by Region (US$ Million) & (2021-2026) Table 105. Asia Drugs for Malaria Revenue by Region (US$ Million) & (2027-2032) Table 106. SAMEA Drugs for Malaria Revenue by Type (2021-2026) & (US$ Million) Table 107. SAMEA Drugs for Malaria Revenue by Type (2027-2032) & (US$ Million) Table 108. SAMEA Drugs for Malaria Revenue by Application (2021-2026) & (US$ Million) Table 109. SAMEA Drugs for Malaria Revenue by Application (2027-2032) & (US$ Million) Table 110. SAMEA Drugs for Malaria Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. SAMEA Drugs for Malaria Revenue by Country (2021-2026) & (US$ Million) Table 112. SAMEA Drugs for Malaria Revenue by Country (US$ Million) & (2027-2032) Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Drugs for Malaria Image Figure 2. Global Drugs for Malaria Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Malaria Market Size Share 2021 VS 2025 VS 2032 Figure 4. Aryl Aminoalcohol Compounds Image Figure 5. Antifolate Compounds Image Figure 6. Artemisinin Compounds Image Figure 7. Global Drugs for Malaria Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Drugs for Malaria Market Size Share 2021 VS 2025 VS 2032 Figure 9. Prevention Image Figure 10. Treatment Image Figure 11. Others Image Figure 12. Global Drugs for Malaria Market Size (US$ Million) & (2021-2032) Figure 13. Global Drugs for Malaria Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Drugs for Malaria Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Drugs for Malaria Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Drugs for Malaria Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Drugs for Malaria Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Drugs for Malaria Revenue Market Share by Type (2021-2032) Figure 20. Global Drugs for Malaria Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Drugs for Malaria Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Drugs for Malaria Revenue Market Share by Application (2021-2032) Figure 23. North America Drugs for Malaria Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Drugs for Malaria Revenue Share by Type (2021-2032) Figure 25. North America Drugs for Malaria Revenue Share by Application (2021-2032) Figure 26. North America Drugs for Malaria Revenue Share by Country (2021-2032) Figure 27. United States Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Drugs for Malaria Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Drugs for Malaria Revenue Share by Type (2021-2032) Figure 32. Europe Drugs for Malaria Revenue Share by Application (2021-2032) Figure 33. Europe Drugs for Malaria Revenue Share by Country (2021-2032) Figure 34. Germany Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Drugs for Malaria Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Drugs for Malaria Revenue Share by Type (2021-2032) Figure 44. China Drugs for Malaria Revenue Share by Application (2021-2032) Figure 45. Asia Drugs for Malaria Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Drugs for Malaria Revenue Share by Type (2021-2032) Figure 47. Asia Drugs for Malaria Revenue Share by Application (2021-2032) Figure 48. Asia Drugs for Malaria Revenue Share by Region (2021-2032) Figure 49. Japan Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Drugs for Malaria Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Drugs for Malaria Revenue Share by Type (2021-2032) Figure 57. SAMEA Drugs for Malaria Revenue Share by Application (2021-2032) Figure 58. SAMEA Drugs for Malaria Revenue Share by Country (2021-2032) Figure 59. Brazil Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Drugs for Malaria Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Aryl Aminoalcohol Compounds
  • Antifolate Compounds
  • Artemisinin Compounds
Applications
  • Prevention
  • Treatment
  • Others
Companies covered
  • Cipla
  • Guilin Pharmaceutical
  • IPCA Laboratories
  • GlaxoSmithKline
  • Mylan Labs
  • Roche
  • Novartis
  • Sanofi Aventis
  • Ajanta Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drugs for Malaria Market by Type
  3. 1.2.1 Global Drugs for Malaria Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Aryl Aminoalcohol Compounds
  5. 1.2.3 Antifolate Compounds
  6. 1.2.4 Artemisinin Compounds
  7. 1.3 Drugs for Malaria Market by Application
  8. 1.3.1 Global Drugs for Malaria Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Prevention
  10. 1.3.3 Treatment
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Drugs for Malaria Market Dynamics
  1. 2.1 Drugs for Malaria Industry Trends
  2. 2.2 Drugs for Malaria Industry Drivers
  3. 2.3 Drugs for Malaria Industry Opportunities and Challenges
  4. 2.4 Drugs for Malaria Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Drugs for Malaria Market Perspective (2021-2032)
  2. 3.2 Global Drugs for Malaria Growth Trends by Region
  3. 3.2.1 Global Drugs for Malaria Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drugs for Malaria Market Size by Region (2021-2026)
  5. 3.2.3 Global Drugs for Malaria Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Drugs for Malaria Revenue by Players
  2. 4.1.1 Global Drugs for Malaria Revenue by Players (2021-2026)
  3. 4.1.2 Global Drugs for Malaria Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Drugs for Malaria Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drugs for Malaria Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Drugs for Malaria Key Players Headquarters & Area Served
  7. 4.4 Global Drugs for Malaria Players, Product Type & Application
  8. 4.5 Global Drugs for Malaria Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Drugs for Malaria Market CR5 and HHI
  11. 4.6.3 2025 Drugs for Malaria Tier 1, Tier 2, and Tier 3
5 Drugs for Malaria Market Size by Type
  1. 5.1 Global Drugs for Malaria Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Drugs for Malaria Revenue by Type (2021-2032)
  3. 5.3 Global Drugs for Malaria Revenue Market Share by Type (2021-2032)
6 Drugs for Malaria Market Size by Application
  1. 6.1 Global Drugs for Malaria Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Drugs for Malaria Revenue by Application (2021-2032)
  3. 6.3 Global Drugs for Malaria Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Cipla
  2. 7.1.1 Cipla Company Information
  3. 7.1.2 Cipla Business Overview
  4. 7.1.3 Cipla Drugs for Malaria Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Cipla Drugs for Malaria Product Portfolio
  6. 7.1.5 Cipla Recent Developments
  7. 7.2 Guilin Pharmaceutical
  8. 7.2.1 Guilin Pharmaceutical Company Information
  9. 7.2.2 Guilin Pharmaceutical Business Overview
  10. 7.2.3 Guilin Pharmaceutical Drugs for Malaria Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Guilin Pharmaceutical Drugs for Malaria Product Portfolio
  12. 7.2.5 Guilin Pharmaceutical Recent Developments
  13. 7.3 IPCA Laboratories
  14. 7.3.1 IPCA Laboratories Company Information
  15. 7.3.2 IPCA Laboratories Business Overview
  16. 7.3.3 IPCA Laboratories Drugs for Malaria Revenue and Gross Margin (2021-2026)
  17. 7.3.4 IPCA Laboratories Drugs for Malaria Product Portfolio
  18. 7.3.5 IPCA Laboratories Recent Developments
  19. 7.4 GlaxoSmithKline
  20. 7.4.1 GlaxoSmithKline Company Information
  21. 7.4.2 GlaxoSmithKline Business Overview
  22. 7.4.3 GlaxoSmithKline Drugs for Malaria Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GlaxoSmithKline Drugs for Malaria Product Portfolio
  24. 7.4.5 GlaxoSmithKline Recent Developments
  25. 7.5 Mylan Labs
  26. 7.5.1 Mylan Labs Company Information
  27. 7.5.2 Mylan Labs Business Overview
  28. 7.5.3 Mylan Labs Drugs for Malaria Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Mylan Labs Drugs for Malaria Product Portfolio
  30. 7.5.5 Mylan Labs Recent Developments
  31. 7.6 Roche
  32. 7.6.1 Roche Company Information
  33. 7.6.2 Roche Business Overview
  34. 7.6.3 Roche Drugs for Malaria Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Roche Drugs for Malaria Product Portfolio
  36. 7.6.5 Roche Recent Developments
  37. 7.7 Novartis
  38. 7.7.1 Novartis Company Information
  39. 7.7.2 Novartis Business Overview
  40. 7.7.3 Novartis Drugs for Malaria Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Novartis Drugs for Malaria Product Portfolio
  42. 7.7.5 Novartis Recent Developments
  43. 7.8 Sanofi Aventis
  44. 7.8.1 Sanofi Aventis Company Information
  45. 7.8.2 Sanofi Aventis Business Overview
  46. 7.8.3 Sanofi Aventis Drugs for Malaria Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Sanofi Aventis Drugs for Malaria Product Portfolio
  48. 7.8.5 Sanofi Aventis Recent Developments
  49. 7.9 Ajanta Pharma
  50. 7.9.1 Ajanta Pharma Company Information
  51. 7.9.2 Ajanta Pharma Business Overview
  52. 7.9.3 Ajanta Pharma Drugs for Malaria Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Ajanta Pharma Drugs for Malaria Product Portfolio
  54. 7.9.5 Ajanta Pharma Recent Developments
8 North America
  1. 8.1 North America Drugs for Malaria Revenue (2021-2032)
  2. 8.2 North America Drugs for Malaria Revenue by Type (2021-2032)
  3. 8.2.1 North America Drugs for Malaria Revenue by Type (2021-2026)
  4. 8.2.2 North America Drugs for Malaria Revenue by Type (2027-2032)
  5. 8.3 North America Drugs for Malaria Revenue Share by Type (2021-2032)
  6. 8.4 North America Drugs for Malaria Revenue by Application (2021-2032)
  7. 8.4.1 North America Drugs for Malaria Revenue by Application (2021-2026)
  8. 8.4.2 North America Drugs for Malaria Revenue by Application (2027-2032)
  9. 8.5 North America Drugs for Malaria Revenue Share by Application (2021-2032)
  10. 8.6 North America Drugs for Malaria Revenue by Country
  11. 8.6.1 North America Drugs for Malaria Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Drugs for Malaria Revenue by Country (2021-2026)
  13. 8.6.3 North America Drugs for Malaria Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Drugs for Malaria Revenue (2021-2032)
  2. 9.2 Europe Drugs for Malaria Revenue by Type (2021-2032)
  3. 9.2.1 Europe Drugs for Malaria Revenue by Type (2021-2026)
  4. 9.2.2 Europe Drugs for Malaria Revenue by Type (2027-2032)
  5. 9.3 Europe Drugs for Malaria Revenue Share by Type (2021-2032)
  6. 9.4 Europe Drugs for Malaria Revenue by Application (2021-2032)
  7. 9.4.1 Europe Drugs for Malaria Revenue by Application (2021-2026)
  8. 9.4.2 Europe Drugs for Malaria Revenue by Application (2027-2032)
  9. 9.5 Europe Drugs for Malaria Revenue Share by Application (2021-2032)
  10. 9.6 Europe Drugs for Malaria Revenue by Country
  11. 9.6.1 Europe Drugs for Malaria Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Drugs for Malaria Revenue by Country (2021-2026)
  13. 9.6.3 Europe Drugs for Malaria Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Drugs for Malaria Revenue (2021-2032)
  2. 10.2 China Drugs for Malaria Revenue by Type (2021-2032)
  3. 10.2.1 China Drugs for Malaria Revenue by Type (2021-2026)
  4. 10.2.2 China Drugs for Malaria Revenue by Type (2027-2032)
  5. 10.3 China Drugs for Malaria Revenue Share by Type (2021-2032)
  6. 10.4 China Drugs for Malaria Revenue by Application (2021-2032)
  7. 10.4.1 China Drugs for Malaria Revenue by Application (2021-2026)
  8. 10.4.2 China Drugs for Malaria Revenue by Application (2027-2032)
  9. 10.5 China Drugs for Malaria Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drugs for Malaria Revenue (2021-2032)
  2. 11.2 Asia Drugs for Malaria Revenue by Type (2021-2032)
  3. 11.2.1 Asia Drugs for Malaria Revenue by Type (2021-2026)
  4. 11.2.2 Asia Drugs for Malaria Revenue by Type (2027-2032)
  5. 11.3 Asia Drugs for Malaria Revenue Share by Type (2021-2032)
  6. 11.4 Asia Drugs for Malaria Revenue by Application (2021-2032)
  7. 11.4.1 Asia Drugs for Malaria Revenue by Application (2021-2026)
  8. 11.4.2 Asia Drugs for Malaria Revenue by Application (2027-2032)
  9. 11.5 Asia Drugs for Malaria Revenue Share by Application (2021-2032)
  10. 11.6 Asia Drugs for Malaria Revenue by Country
  11. 11.6.1 Asia Drugs for Malaria Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Drugs for Malaria Revenue by Country (2021-2026)
  13. 11.6.3 Asia Drugs for Malaria Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drugs for Malaria Revenue (2021-2032)
  2. 12.2 SAMEA Drugs for Malaria Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Drugs for Malaria Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Drugs for Malaria Revenue by Type (2027-2032)
  5. 12.3 SAMEA Drugs for Malaria Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Drugs for Malaria Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Drugs for Malaria Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Drugs for Malaria Revenue by Application (2027-2032)
  9. 12.5 SAMEA Drugs for Malaria Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Drugs for Malaria Revenue by Country
  11. 12.6.1 SAMEA Drugs for Malaria Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Drugs for Malaria Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Drugs for Malaria Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst